Опыт применения глюкагоноподобного пептида-1 у пациентов с ожирением

Abstract

Objective. To study the glucagon-like peptide-1 liraglutide use in patients with obesity. Patients and methods. From October 2018 to November 2021, 60 people (34 women and 26 men) aged 36 to 72 years were examined, with a body mass index of >30 kg/m2 and with diabetes or insulin resistance. The duration of inclusion was 2 years, the duration of the observation period was 6 months. Before prescribing medicine, we studied the anamnesis, determination of anthropometric indicators, and the monitoring of laboratory parameters of patients. Liraglutide was prescribed – a starting dose of 0.6 mg / day subcutaneously with an increasing of 0.6 mg at intervals of at least 1 week, to improve gastrointestinal tolerance, up to 3 mg / day subcutaneously for 6 months. Results. According to the results of bioimpedansometry, a significant decrease in body fat mass in kilograms was revealed (the percentage of fat mass also decreased), increasing of musculoskeletal mass, a significant increase in specific metabolism, phase angle was observed. Decreasing of active cell mass was also significantly observed. According to the results of monitoring of blood test and a biochemical analysis, a significant decrease in fasting blood glucose levels was revealed in 88% of women, in 78% of men, decreasing in serum insulin in 82% of women and 65% of men. There were no significant differences in the decrease level of low-density lipoproteins and cholesterol and evaluating the results of analysis NOMA index Significant decrease in body weight and BMI was not revealed, according to the results of anthropometry, but there was an actual decrease in body weight. All three groups were with the same stage of obesity, both in men and women. Conclusion. The study shows that Liraglutide led to the decrease in body fat mass of patients, fasting blood glucose and serum insulin, which is consistent with the results of other studies. Sex differences in the effectiveness of therapy were revealed, decreasing in fasting blood glucose levels was observed in 88% of women and 78% of men, decreasing of serum insulin – in 82% of women and 65% of men. Key words: glucagon-like peptide-1, overweight, obesity, diabetes